ArticleWorld journal of urology2025

Comment on do patients with intermediate-risk renal carcinoma who receive adjuvant pembrolizumab really benefit in recurrence-free survival? Analysis of a cohort of nephrectomies over 10 years.

No numbers read from the abstract.

Not cited yet